JUJames E. Udelson

James E. Udelson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James E. Udelson has a total of 308 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fluid Management of Acute Heart Failure With the Reprieve System

    by James E. Udelson, Ali Javaheri, Marat Fudim, Kevin Damman, Jan Biegus, Aasim Afzal, Alpesh N. Amin, Daniel Bensimhon, Jason J. Bischof, Eugene S. Chung, et al.


  • Open Access

    Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure

    by James E. Udelson, Jan Bělohlávek, Andrej Dukát, Justin Ezekowitz, Sorel Goland, Bela Merkely, Eileen O’MEara, Mark C. Petrie, Piotr Ponikowski, Michele Senni, et al.


  • Open Access

    Interpreting Health Status Measures in Patients With Heart Failure—What Counts

    by James E. Udelson, Clyde W. Yancy, Gregg C. Fonarow

    Contemporary randomized clinical trials (RCTs) in heart failure (HF) now consistently inform clinical outcomes such as cardiovascular death or HF

  • Open Access

    Relationship Between Infarct Artery, Myocardial Injury, and Outcomes After Primary Percutaneous Coronary Intervention in ST‐Segment–Elevation Myocardial Infarction

    by Suzanne de Waha, Manesh R. Patel, Holger Thiele, James E. Udelson, Christopher B. Granger, Ori Ben‐Yehuda, Lak Kotinkaduwa, Björn Redfors, Ingo Eitel, Harry P. Selker, et al.

    Background: The extent to which infarct artery impacts the extent of myocardial injury and outcomes in patients with ST‐segment–elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention is uncertain. Methods and Results: We performed a pooled analysis using individual patient data from 7 randomized STEMI trials in which myocardial injury within 30 days after primary percutaneous coronary intervention was assessed in 1774 patients by cardiac magnetic resonance (n=1318) or technetium‐99m sestamibi single‐photon emission computed tomography (n=456). Clinical follow‐up was performed at a median duration of 351 days (interquartile range, 184–368 days). Infarct size and outcomes were assessed in anterior (infarct vessel=left anterior descending) versus nonanterior (non–left anterior descending) STEMI. Median infarct size (percentage left ventricular myocardial mass) was larger in patients with anterior compared with nonanterior STEMI (19.7% [interquartile range, 9.4%–31.7%] versus 12.6% [interquartile range, 5.1%–20.5%]; P P =0.04) and heart failure hospitalization (4.4% versus 2.6%; adjusted HR, 1.96 [95% CI, 1.15–3.36]; P =0.01). Infarct size was a predictor of subsequent all‐cause mortality or heart failure hospitalization in anterior STEMI (adjusted HR per 1% increase, 1.05 [95% CI, 1.03–1.07]; P P =0.19). The P value for this interaction was 0.04. Conclusions: Anterior STEMI was associated with substantially greater myonecrosis after primary percutaneous coronary intervention compared with nonanterior STEMI, contributing in large part to the worse prognosis in patients with anterior infarction.


  • Realigning Priorities in the Evaluation and Management of Patients With Heart Failure

    by James E. Udelson, Gregg C. Fonarow, Robert O. Bonow

    In this issue of JAMA Cardiology, Perera and coauthors report that myocardial viability status has no influence on the outcomes associated with either percutane


  • Open Access

    The second phase-3 multi-center trial of flurpiridaz F-18 PET myocardial perfusion imaging for coronary artery disease evaluation

    by J Maddahi, D Agostini, T Bateman, J J Bax, R S B Beanlands, D S Berman, S Dorbala, E V Garcia, G Heller, J M Knuuti, et al.

    Background/Introduction: Flurpiridaz F-18 (flurpiridaz) is a novel PET myocardial perfusion imaging tracer with outstanding imaging characteristics. Purpose: To further assess the diagnostic efficacy and safety of flurpiridaz PET for the detection and evaluation of coronary artery disease (CAD) defined as >50% stenosis by quantitative invasive coronary angiography (ICA) in a multi-center prospective international clinical trial. The primary end point was to assess the diagnostic efficacy (sensitivity and specificity) of flurpiridaz PET MPI for the detection of CAD. The secondary end points were to compare the diagnostic performance of flurpiridaz PET vs. Tc-99m SPECT in the detection of CAD in all patients and in the clinically important subgroups of women, obese [body mass index (BMI) ≥30 kg/m2], and diabetics. Also, PET and Tc-99m SPECT were compared for defect severity/extent, image quality, confidence of interpretation and radiation dose to patients. The safety of flurpiridaz PET was also evaluated. Methods: 730 patients with suspected CAD from 48 clinical sites in US, Canada and Europe were enrolled. Patients underwent 1-day rest/stress (pharmacological or exercise) flurpiridaz PET and 1- or 2-day rest-stress Tc-99m labeled SPECT before ICA. PET and SPECT images were read by 3 experts blinded to clinical and ICA data. ICA was quantified by a core laboratory expert blinded to clinical and image data. Results: 578 patients (age, 63.7±9.5 years) were evaluable. Flurpiridaz PET met the prespecified primary endpoint of the study; sensitivity and specificity were significantly higher than the prespecified threshold value by two of the three readers. The secondary endpoints were also met in the overall population, in women, in obese patients, and in diabetics. Flurpiridaz PET ROC area under the curves were significantly higher than SPECT in the overall population (0.80 vs 0.68, p<0.0001), in women (0.84 vs 0.70, p<0.01), and in obese patients (0.79 vs 0.67, p<0.001), but not in diabetics (0.76 vs 0.69, p=0.088). Flurpiridaz PET was also superior to SPECT for assessment of defect extent/severity (p<0.0001). Image quality (% excellent or good) of flurpiridaz PET was significantly better than SPECT for rest images (93% vs 72%, p<0.0001), pharmacological stress images (96% vs 78%, p<0.0001), and treadmill exercise images (97% vs 87%, p<0.05). Radiation exposure, evaluated in 604 dosed patients, was less for PET than same-day rest/stress SPECT using either Tetrofosmin or Sestamibi with 6.25 mSv for flurpiridaz PET, 9.86 mSv for 99mTc-tetrofosmin SPECT and 12.41 mSv for 99mTc-sestamibi SPECT. Conclusion: This second flurpiridaz PET myocardial perfusion imaging multicenter international trial demonstrates that flurpiridaz has promise as a new tracer for detection and evaluation of coronary artery disease. This is particularly so in women and patients with BMI≥30.

  • No-Implant Interatrial Shunt for HFpEF

    by James E. Udelson, Colin M. Barker, Gerard Wilkins, Benjamin Wilkins, Robert Gooley, Siobhan Lockwood, Brian J. Potter, Christopher U. Meduri, Peter S. Fail, Darrell J. Solet, et al.


  • Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments

    by Iacopo Olivotto, James E Udelson, Maurizio Pieroni, Claudio Rapezzi

    Heart failure with preserved ejection fraction (HFpEF) is a major driver of cardiac morbidity and mortality in developed countries, due to ageing populations and the increasing prevalence of comorbidities. While heart failure with reduced ejection fraction is dominated by left ventricular impairment, HFpEF results from a complex interplay of cardiac remodelling, peripheral circulation, and concomitant features including age, hypertension, obesity, and diabetes. In an important subset, however, HFpEF is subtended by specific diseases of the myocardium that are genetically determined, have distinct pathophysiology, and are increasingly amenable to targeted, innovative treatments. While each of these conditions is rare, they collectively represent a relevant subset within HFpEF cohorts, and their prompt recognition has major consequences for clinical practice, as access to dedicated, disease-specific treatments may radically change the quality of life and outcome. Furthermore, response to standard heart failure treatment will generally be modest for these individuals, whose inclusion in registries and trials may dilute the perceived efficacy of treatments targeting mainstream HFpEF. Finally, a better understanding of the molecular underpinnings of monogenic myocardial disease may help identify therapeutic targets and develop innovative treatments for selected HFpEF phenotypes of broader epidemiological relevance. The field of genetic cardiomyopathies is undergoing rapid transformation due to recent, groundbreaking advances in drug development, and deserves greater awareness within the heart failure community. The present review addressed existing and developing therapies for genetic causes of HFpEF, including hypertrophic cardiomyopathy, cardiac amyloidosis, and storage diseases, discussing their potential impact on management and their broader implications for our understanding of HFpEF at large.


  • Straining for Surrogacy

    by James E. Udelson, Benjamin S. Wessler